China's drug regulator approved Hualan Biological Engineering (SHE:002007) subsidiary Hualan Biological Vaccine's clinical trial for its novel adjuvanted influenza virus split vaccine.
The vaccine helps with immunity against influenza, especially in elderly and immunocompromised patients, according to a Saturday disclosure to the Shenzhen bourse.